New registry to monitor Real-World effects of NMOSD treatments

NCT ID NCT05966467

Recruiting now Knowledge-focused Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs like eculizumab or ravulizumab. It will collect information on relapses, safety, and quality of life over many years to understand how these treatments work in everyday life. About 122 participants will join from multiple countries, and no new treatments are being tested—just real-world data gathered.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuromyelitis optica neuromyelitis optica spectrum disorder with anti-AQP4 antibodies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AQP4+ NMOSD NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Clinical Trial Site
NOT_YET_RECRUITING

Chapel Hill, North Carolina, 27599, United States
Clinical Trial Site
RECRUITING

Columbus, Ohio, 43215, United States
Clinical Trial Site
RECRUITING

Plano, Texas, 75024, United States
Clinical Trial Site
RECRUITING

Milwaukee, Wisconsin, 53215, United States
Clinical Trial Site
RECRUITING

Buenos Aires, Argentina
Clinical Trial Site
NOT_YET_RECRUITING

Buenos Aires, Argentina
Clinical Trial Site
RECRUITING

Buenos Aires, Argentina
Clinical Trial Site
RECRUITING

Buenos Aires, Argentina
Clinical Trial Site
RECRUITING

Burnaby, British Columbia, Canada
Clinical Trial Site
NOT_YET_RECRUITING

Beijing, China
Clinical Trial Site
NOT_YET_RECRUITING

Guangzhou, China
Clinical Trial Site
NOT_YET_RECRUITING

Henan, China
Clinical Trial Site
NOT_YET_RECRUITING

Shanghai, China
Clinical Trial Site
NOT_YET_RECRUITING

Sichuan, China
Clinical Trial Site
NOT_YET_RECRUITING

Wuhan, China
Clinical Trial Site
RECRUITING

Dresden, Germany
Clinical Trial Site
RECRUITING

Essen, Germany
Clinical Trial Site
NOT_YET_RECRUITING

München, Germany
Clinical Trial Site
RECRUITING

Naples, Italy
Clinical Trial Site
RECRUITING

Fukuoka, Japan
Clinical Trial Site
RECRUITING

Kawasaki, Japan
Clinical Trial Site
RECRUITING

Miyagi, Japan
Clinical Trial Site
NOT_YET_RECRUITING

Tokyo, Japan
Clinical Trial Site
RECRUITING

Daejeon, South Korea
Clinical Trial Site
RECRUITING

Gyeonggi-do, South Korea
Clinical Trial Site
RECRUITING

Seoul, South Korea
Clinical Trial Site
RECRUITING

Seoul, South Korea
Clinical Trial Site
RECRUITING

Seoul, South Korea
Clinical Trial Site
RECRUITING

Seoul, South Korea
Clinical Trial Site
RECRUITING

Seoul, South Korea
Clinical Trial Site
RECRUITING

Seoul, South Korea
Research Site
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.